228 related articles for article (PubMed ID: 30539376)
1. Emerging Immunotherapies for Parkinson Disease.
Zella SMA; Metzdorf J; Ciftci E; Ostendorf F; Muhlack S; Gold R; Tönges L
Neurol Ther; 2019 Jun; 8(1):29-44. PubMed ID: 30539376
[TBL] [Abstract][Full Text] [Related]
2. Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson's Disease.
Zella MAS; Metzdorf J; Ostendorf F; Maass F; Muhlack S; Gold R; Haghikia A; Tönges L
Cells; 2019 Jan; 8(2):. PubMed ID: 30708997
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Parkinson's disease: Current status and future directions.
Chatterjee D; Kordower JH
Neurobiol Dis; 2019 Dec; 132():104587. PubMed ID: 31454546
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic approaches to target alpha-synuclein pathology.
Brundin P; Dave KD; Kordower JH
Exp Neurol; 2017 Dec; 298(Pt B):225-235. PubMed ID: 28987463
[TBL] [Abstract][Full Text] [Related]
5. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
Oertel W; Schulz JB
J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
[TBL] [Abstract][Full Text] [Related]
6. Effects of single and combined immunotherapy approach targeting amyloid β protein and α-synuclein in a dementia with Lewy bodies-like model.
Mandler M; Rockenstein E; Overk C; Mante M; Florio J; Adame A; Kim C; Santic R; Schneeberger A; Mattner F; Schmidhuber S; Galabova G; Spencer B; Masliah E; Rissman RA
Alzheimers Dement; 2019 Sep; 15(9):1133-1148. PubMed ID: 31378574
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
George S; Brundin P
J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
[TBL] [Abstract][Full Text] [Related]
8. Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders.
Tolmasov M; Djaldetti R; Lev N; Gilgun-Sherki Y
Expert Rev Neurother; 2016 May; 16(5):505-13. PubMed ID: 26959397
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
[TBL] [Abstract][Full Text] [Related]
10. Increased Immune Activation by Pathologic α-Synuclein in Parkinson's Disease.
Grozdanov V; Bousset L; Hoffmeister M; Bliederhaeuser C; Meier C; Madiona K; Pieri L; Kiechle M; McLean PJ; Kassubek J; Behrends C; Ludolph AC; Weishaupt JH; Melki R; Danzer KM
Ann Neurol; 2019 Oct; 86(4):593-606. PubMed ID: 31343083
[TBL] [Abstract][Full Text] [Related]
11. Active immunization therapies for Parkinson's disease and multiple system atrophy.
Schneeberger A; Tierney L; Mandler M
Mov Disord; 2016 Feb; 31(2):214-24. PubMed ID: 26260853
[TBL] [Abstract][Full Text] [Related]
12. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
Miraglia F; Betti L; Palego L; Giannaccini G
Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
[TBL] [Abstract][Full Text] [Related]
13. New therapeutic approaches to target alpha-synuclein in Parkinson's disease: The role of immunotherapy.
Fernández-Valle T; Gabilondo I; Gómez-Esteban JC
Int Rev Neurobiol; 2019; 146():281-295. PubMed ID: 31349931
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.
Qin H; Buckley JA; Li X; Liu Y; Fox TH; Meares GP; Yu H; Yan Z; Harms AS; Li Y; Standaert DG; Benveniste EN
J Neurosci; 2016 May; 36(18):5144-59. PubMed ID: 27147665
[TBL] [Abstract][Full Text] [Related]
15. Lymphocyte-Activation Gene 3 (LAG3) Protein as a Possible Therapeutic Target for Parkinson's Disease: Molecular Mechanisms Connecting Neuroinflammation to α-Synuclein Spreading Pathology.
Angelopoulou E; Paudel YN; Villa C; Shaikh MF; Piperi C
Biology (Basel); 2020 Apr; 9(4):. PubMed ID: 32340360
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies.
Shin J; Kim HJ; Jeon B
J Mov Disord; 2020 Jan; 13(1):11-19. PubMed ID: 31847513
[TBL] [Abstract][Full Text] [Related]
17. Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.
Török N; Majláth Z; Szalárdy L; Vécsei L
Expert Opin Investig Drugs; 2016 Nov; 25(11):1281-1294. PubMed ID: 27677932
[TBL] [Abstract][Full Text] [Related]
18. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
[TBL] [Abstract][Full Text] [Related]
19. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
[TBL] [Abstract][Full Text] [Related]
20. Development of Passive Immunotherapies for Synucleinopathies.
Bergström AL; Kallunki P; Fog K
Mov Disord; 2016 Feb; 31(2):203-13. PubMed ID: 26704735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]